fenofibrate + mesalamine

Fenofibrate + mesalamine is a combination therapy investigated for the treatment of mild to moderate ulcerative colitis. Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist primarily used to lower cholesterol and triglyceride levels, while mesalamine (also known as 5-aminosalicylic acid) is an anti-inflammatory aminosalicylate commonly used in inflammatory bowel disease. In clinical studies, the addition of fenofibrate to standard mesalamine therapy resulted in improved digestive symptoms, reduced inflammatory markers (such as NLRP3 and fecal calprotectin), and increased levels of SIRT1 and AMPK, suggesting enhanced anti-inflammatory effects compared to mesalamine alone. The combination was found safe and tolerable for patients with mild to moderate ulcerative colitis[1][2].